Palabras clave
Agrandamiento gingival
bloqueador de canales de calcio.
Cómo citar
Resumen
ResumenEs bien conocido que el tratamiento con diversos tipos de medicamentos puede producir en las encías un crecimiento de este tejido. Se reporta que medicamentos tales como los bloqueadores de los canales de calcio, inmunosupresores, anticonvulsivantes pueden expresar esos efectos laterales. La nifedipina es la que principalmente se reporta que produce agrandamientos gingivales, al ser utilizada durante tratamientos largos para trastornos cardiovasculares, angina de pecho e hipertensión. Se presenta un caso de paciente varón de 60 años de edad, hipertenso, tratado con nifedipina, con agrandamientos gingivales. Se realiza fase higiénica y terapia quirúrgica con electro cirugía. La evolución y predecibilidad fueron favorables. (Duazary 2009 I; 51-55)AbstractIt is well known that chronic medication with various drugs may cause gingival overgrowth. It has been reported that gingival overgrowth is induced by drugs such as calcium channel blockers and immunosuppressants. Nifedipine is most frequently reported to induce gingival overgrowth during long-term treatment of cardiovascular disorders such as hypertension and angina pectoris. A case of a 60 year old male patient with hypertension treated with nifedipine is presented. Electrosurgery treatment was performed; the evolution and prediction are favorable.Key Words: Nifedipine; Gingival Overgrowth; Calcium Cannel Blocker.Citas
Khera P, Zirwas MJ, English JC 3rd. Diffuse gingival enlargement. J Am Acad Dermatol. 2005;52:491-9
Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug induced gingival overgrowth. J Clin Periodontol 1996; 23:165-75
Brown, R.S.; Beaver, W.T. & Bottomley, W.K. On the mechanism of drug induced gingival hyperplasia. J Oral Pathol Med. 1991;20: 201-9.
Fujii A, Matsumoto H, Nakao S, Teshigawara H, Akimoto Y. Effect of calcium channel blockers on cell proliferation, DNA synthesis and collagen synthesis of cultured gingival fibroblasts derived from human nifedipine responders and non responders. Arch Oral Biol. 1994;39:99 –104.
Trackman PC, Kantarci A. Connective tissue metabolism and gingival overgrowth. Crit Rev Oral Biol Med. 2004;15:165–75.
Wang PL. Inhibition by tranilast of nifedipine-induced proliferation of cultured human gingival fibroblasts. Eur J Pharmacol. 2004; 498:79–81.
Varnfield M, Botha SJ. Drug induced gingival hyperplasia. A review. SADJ 2000; 55:632-41.
Ball DE, McLaughlin WS, Seymour RA, Kamali F. Plasma and saliva concentrations of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in relation to the incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients. J Periodontol. 1996; 67:597-602.
Ellis JS, Seymour RA, Monkman SS, Idle JR. Disposition of nifedipine in plasma and gingival crevicular fluid in relation to drug-induced gingival overgrowth. J Periodont Res. 1993;28: 373-378
Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J Periodontol. 1999; 70:63-7.
Ramon Y, Behar S, Kishon Y y Engelberg IS: Gingival Hyperplasia caused by nifedipine-A preliminary report. Int J Cardiol. 1984;5:195-204.
Bullon P, Machuca G, Armas J, Rojas J, Jiménez J. The gingival inflammatory infíltrate in cardiac patients treated with calcium antagonist. J Clin Periodontol. 2001;28:897-903
Somacarrera ML, Hernandez G, Acero J, Moskow MS. Localization of gingival overgrowth in heart transplant patients undergoing cyclosporin therapy. J Periodontol. 1994;65:666-70.
Miranda J, Brunet L, Roset P, Berini L, Farre M, Mendieta C. Prevalence and risk of gingival enlargement in patients treated with nifedipine. J Periodontol. 2001; 72:605-11.
Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowths. Aust Dent J. 1999;44:219-32.
Bullon P, Gallardo I, Goteri G, Rubini C, Battino M, Ribas J, Newman H.N. Nifedipine and Cyclosporin Affect Fibroblast Calcium and Gingiva. J Dent Res. 2007;86:357-362.
Seymour RA and Heasman PA. Drugs and the periodontum. J Clin Periodontol. 1988;15:1-16.
Lucas RM, Howell LP, Wall BA. Nifedipine-induced gingival hiperplasia. A histochemical and ultrastructural study. J Periodontol. 1985; 56: 211-215.
González-Jaranay M y Mesa P: Hiperplasia gingival inducida por nifedipino. Rev Eur Odontoestomatol 1991;3:127-130.
Gelfand EW, Cheung RK, Mills GB. The cyclosporines inhibit lymphocyte activation at more than one site. J Immunol. 1987;138:1115-1120.
Ellis JS, Averley PA, Preshaw PM, Steele JG, Seymour RA, Thomason JM. Change in cardiovascular risk status after dental clearance. Br Dent J. 2007;202:543-4.
Seymour RA, Preshaw PM, Thomason JM, Ellis JS, Steele JG. Cardiovascular diseases and periodontology. J Clin Periodontol. 2003;30:279-92.
Seymour RA. Dentistry and the medically compromised patient. Surgeon. 2003;1:207-14.
Radfar L, Suresh L. Medical profile of a dental school patient population. J Dent Educ. 2007;71:682-6.
Kellogg SD, Gobetti JP. Hypertension in a dental school patient population. J Dent Educ. 2004;68:956-64.
Mavrogiannis M, Ellis JS, Thomason JM, Seymour RA. The management of drug-induced gingival overgrowth. J Clin Periodontol. 2006;33:434-9.
Mavrogiannis M, Ellis JS, Seymour RA, Thomason JM. The efficacy of three different surgical techniques in the management of drug-induced gingival overgrowth. J Clin Periodontol. 2006;33:677-82.
Pilloni A, Camargo PM, Carere M, Carranza FA Jr. Surgical treatment of cyclosporine A- and nifedipine-induced gingival enlargement: gingivectomy versus periodontal flap. J Periodontol. 1998;69:791-7.
Gibson RM, Meechan JG. The effects of antihypertensive medication on dental treatment. Dent Update. 2007;34:70-2.
Bavitz JB. Dental management of patients with hypertension. Dent Clin North Am. 2006;50:547-62.
Hall EE. Prevention and treatment considerations in patients with drug-induced gingival enlargement. Curr Opin Periodontol. 1997;4:59-63.Revista de la Facultad de Ciencias de la Salud 55 Díaz A., Arevalo L. y Fonseca M.
Ilgenli T, Atilla G, Baylas H. Effectiveness of periodontal therapy in patients with drug-induced gingival overgrowth. Long-term results. J Periodontol. 1999;70:967-72.
Bosco AF, Bonfante S, Luize DS, Bosco JM, Garcia VG. Periodontal plastic surgery associated with treatment for the removal of gingival overgrowth. J Periodontol. 2006;77:922-8.
Darbar UR, Hopper C, Speight PM, Newman HN. Combined treatment approach to gingival overgrowth due to drug therapy. J Clin Periodontol. 1996;23:941-4.
Bullon P, Machuca G, Martinez-Sahuquillo A, Rios JV, Velasco E, Rojas J, Lacalle JR. Evaluation of gingival and periodontal conditions following causal periodontal treatment in patients treated with nifedipine and diltiazem. J Clin Periodontol. 1996;23:649-57.
Sakellari D, Vouros ID, Aristodemou E, Konstantinidis AB, Socransky S, Goodson M. Tetracycline fibers as an adjunct in the treatment of nifedipine-induced gingival enlargement. J Periodontol. 2005;76:1034-9.
Kinane DF, Marshall GJ. Periodontal manifestations of systemic disease. Aust Dent J. 2001 Mar;46(1):2-12.
Kara C, Demir T, Tezel A. Effectiveness of periodontal therapies on the treatment of different aetiological factors induced gingival overgrowth in puberty. Int J Dent Hyg. 2007;5:211-7.
Hancock RH, Swan RH. Nifedipine-induced gingival overgrowth. Report of a case treated by controlling plaque. J Clin Periodontol. 1992;19:12-4.
Ciantar M. Nifedipine-induced gingival overgrowth: remission following non-surgical therapy. Dent Update. 1996;23:374-7.
Jaimes M, Muñante J, Olate S, Rodriguez-Chessa JG, de Albergaria-Barbosa JR, Mazzonetto R, et al. Inflammatory fibrous hyperplasia treated with a modified vestibuloplasty: a case report. J Contemp Dent Pract. 2008 Mar 1;9(3):135-41.
Cohen D, Bhattacharyya I. Case of the month: drug-induced hyperplasia. Todays FDA. 2008 Mar;20(3):2
No se permite un uso comercial de la obra original ni de las posibles obras derivadas, la distribución de las cuales se debe hacer con una licencia igual a la que regula la obra original.